Simpler Grants.gov #HT942526ALSRPTDA

Army Solicits ALS Therapeutic Development Research Proposals

The Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA), is inviting research proposals for the ALS Research Program Therapeutic Development Award. - Government Buyer: - Department of the Army - U.S. Army Medical Research Acquisition Activity (USAMRAA) - Products/Services Requested: - Research services to advance ALS therapeutic leads from preclinical validation through FDA IND-enabling studies - Required parallel development of mechanism-specific, predictive, or pharmacodynamic biomarkers relevant to the therapeutic approach - Key Requirements: - Applicants must have lead compounds in hand and proof-of-concept efficacy data in at least one preclinical ALS model - Projects focused solely on diagnostic/prognostic biomarkers or on candidates already granted an IND are not eligible - Funding: - Up to $12 million available, with approximately six awards anticipated - No specific OEMs or vendors are named, as this is a research grant opportunity, not a product procurement - Place of Performance: - USAMRAA (U.S. Army Medical Research Acquisition Activity)

Description

The fiscal year 2026 Amyotrophic Lateral Sclerosis Research Program Therapeutic Development Award supports research from preclinical validation of therapeutic leads through FDA Investigational New Drug enabling studies. The research is expected to be empirical and product-driven, requiring applicants to have lead compounds in hand with proof-of-concept efficacy data in at least one appropriate preclinical ALS model system. A critical component is the development of mechanism-specific, predictive biomarkers in parallel to the therapeutic effort. Therapeutic candidates already granted an IND are not eligible for this award.

View original listing